HLA
BDTX icon

Hamilton Lane Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Hamilton Lane Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,644
Closed -$469K – 70
2020
Q4 		$469K Buy
14,644
+4,663
+47% +$153K 0.17% 46
2020
Q3 		$302K Buy
+9,981
New +$304K 0.15% 42

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Hamilton Lane Advisors's BDTX Position: Q1 2021 in Review

Hamilton Lane Advisors sold out of Black Diamond Therapeutics (BDTX) in Q1 2021, closing a stake of 14,644 shares — an estimated $469K sold.

Hamilton Lane Advisors first reported a position in BDTX in Q3 2020 and held it in 2 quarters. The position peaked at $469K in Q4 2020. 113 funds tracked by Wall St. Rank hold BDTX as of Q1 2021.

  • Hamilton Lane Advisors reported no remaining Black Diamond Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 14,644 Black Diamond Therapeutics shares in Q1 2021, an estimated $469K.
  • Hamilton Lane Advisors first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 2 quarters.
  • Hamilton Lane Advisors's Black Diamond Therapeutics position peaked at $469K in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2021.

Based on Hamilton Lane Advisors's 13F filing for Q1 2021, filed 13 Apr 2021.